China-based biotechnology company Asieris Pharmaceuticals revealed on Wednesday that the first patient has been enrolled and administered in its global, multi-centered, Phase III clinical trial of its photodynamic drug-device combination product, APL-1702 (Cevira).
APL-1702 is being developed for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), a pre-cancerous condition caused by a persistent HPV infection.
According to the company, there are approximately 10 million cases of high-grade disease and over 500,000 new cases of cervical cancer worldwide annually. Currently, treatment options include surgical excisions, primarily LEEP/LLETZ and CKC. However, these surgical treatment methods may cause risks including bleeding, infection, and/or damage to the cervix.
Dr John Zhuang, chief operating officer at Asieris and APL-1702's project leader, commented: "APL-1702 provides a novel treatment option for HSIL patients, minimizing pain and side effects associated with surgical approaches. We firmly believe it is a breakthrough therapy with potential to be the first non-surgical treatment agnostic of HVP sub-type for cervical pre-cancerous lesions in the world," commented . "Asieris will continue to focus on genitourinary tumors and related diseases, fulfill significant unmet medical needs, thereby bringing substantial relief to the patients."
Icon Supports Pfizer, BioNTech on the Investigational COVID-19 Vaccine Trial
Johnson & Johnson declares dividend of USD1.01 per share for Q1 2021
Neoteryx's mitra microsamples help NIH measure SARS-CoV-2 raised antibodies with 99-100% accuracy
Bausch Health's DEXAVEN receives Polish new indication for the treatment of COVID-19